Tamsulosin detailed information

Tamsulosin detailed information
Clinical data
Pregnancy; category	B2 (Aust);
Routes of; administration	oral
ATC code	G04CA02 (WHO) ;
Legal status
Legal status	Schedule 4 (Aust); POM (UK);
Pharmacokinetic data
Bioavailability	100% (oral)
Metabolism	hepatic
Elimination half-life	9–13 hours
Excretion	76% renal
Identifiers
	IUPAC name (R)-5-(2-(2-(2-ethoxyphenoxy)ethylamino)propyl)-; 2-methoxybenzenesulfonamide;
CAS Number	106133-20-4;
PubChem CID	129211;
DrugBank	APRD00036;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C20H28N2O5S
Molar mass	408.51

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

For patient information, click here

Overview

Tamsulosin (rINN) (Template:PronEng) is an α_1a-selective alpha blocker used in the symptomatic treatment of benign prostatic hyperplasia (BPH). Tamsulosin was developed by Yamanouchi Pharmaceuticals (now part of Astellas Pharma) and is marketed by various companies under licence, including Boehringer-Ingelheim and CSL. As of 2006, tamsulosin hydrochloride extended-release tablets are marketed under the trade name Flomaxtra. It was formerly marketed as modified-release capsules under the trade name Flomax.

Clinical use

Adverse effects

Two ADRs (Adverse Drug Reactions) have been reported:

Immunologic: It contains a sulfa moiety, thus causing typical reactions to sulfa drugs.
Ophthalmologic: Patients taking tamsulosin are prone to a complication known as floppy iris syndrome during cataract surgery. Adverse outcomes of the surgery are greatly reduced by the surgeon's prior knowledge of the patient's history with this drug, and thus having the option of alternative techniques. [2]

Tamsulosin has also affected the sexual function in men. Tamsulosin can cause males to experience retrograde ejaculation.

Clinical comparison

Although prostate specific, it does not have the prostate apoptotic effects of other alpha-blockers such as doxazosin and terazosin.

External links

Tamsulosin (systemic) – information from USP DI Advice for the Patient
Flomax (drugs.com) – U.S. product information
Flomax (Official Site) – Official Site

de:Tamsulosin

Template:WikiDoc Sources

v t e Urologicals (G04)
Acidifiers	Ammonium chloride, Calcium chloride
Urinary antispasmodics (primarily antimuscarinics)	Darifenacin, Emepronium, Fesoterodine, Flavoxate, Meladrazine, Oxybutynin, Propiverine, Solifenacin, Terodiline, Tolterodine, Trospium
For erectile dysfunction	prostaglandins: Alprostadil PDE5 inhibitors: Avanafil - Sildenafil - Tadalafil - Udenafil - Vardenafil alpha blockers: Moxisylyte - Phentolamine - Yohimbine others: Apomorphine - Papaverine
Other urologicals	Acetohydroxamic acid, Collagen, Dimethyl sulfoxide, Magnesium hydroxide, Pentosan polysulfate, Phenazopyridine, Phenyl salicylate, Succinimide
For benign prostatic hypertrophy	5α-reductase inhibitors: Dutasteride, Finasteride Alpha blockers: Alfuzosin, Doxazosin, Silodosin, Tamsulosin, Terazosin Herbals: Pygeum africanum, Serenoa repens

Clinical data
Pregnancy category	B2 (Aust)
Routes of administration	oral
ATC code	G04CA02 (WHO)
Legal status
Legal status	Schedule 4 (Aust) POM (UK)
Pharmacokinetic data
Bioavailability	100% (oral)
Metabolism	hepatic
Elimination half-life	9–13 hours
Excretion	76% renal
Identifiers
IUPAC name (R)-5-(2-(2-(2-ethoxyphenoxy)ethylamino)propyl)- 2-methoxybenzenesulfonamide
CAS Number	106133-20-4
PubChem CID	129211
DrugBank	APRD00036
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₀H₂₈N₂O₅S
Molar mass	408.51